tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Cross, 107 are a BUY (100%).
Analyst Matthew Cross, currently employed at TRUIST, carries an average stock price target met ratio of 25% that have a potential upside of 14.35% achieved within 11 days. Previously, Matthew Cross worked at JONESTRADING.
Matthew Cross’s has documented 9 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SYRS, Syros Pharmaceuticals at 17-May-2022.
Analyst best performing recommendations are on SYRS (SYROS PHARMACEUTICALS).
The best stock recommendation documented was for SYRS (SYROS PHARMACEUTICALS) at 5/17/2022. The price target of $10 was fulfilled within 21 days with a profit of $2.23 (28.7%) receiving and performance score of 13.67.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$10
$5.76 (135.85%)
$10
3 months 8 days ago
(09-Aug-2024)
0/9 (0%)
$4.9 (96.08%)
Buy
$8
$3.76 (88.68%)
$25
1 years 1 months ago
(17-Oct-2023)
0/10 (0%)
$6.16 (334.78%)
Hold
$14
1 years 1 months ago
(17-Oct-2023)
2/3 (66.67%)
$6.42 (84.70%)
362
Buy
2 years 10 months 22 days ago
(27-Dec-2021)
0/1 (0%)
$9.48 (75.72%)
Buy
$20
$15.76 (371.70%)
$20
5 years 4 months 22 days ago
(26-Jun-2019)
0/4 (0%)
$13.77 (221.03%)
What Year was the first public recommendation made by Matthew Cross?
